Ge advantage windows 3d workstation

The individuals under study underwent contrast-enhanced CT using one of the following systems: Sensation 64 CT (Siemens, Munich, Germany) or Sensation 16 CT (Siemens, Munich, Germany). Triple-phase CT examinations were conducted, including non-enhanced, arterial, and portal vein phases. The abdomen scouts were acquired from the dome of the diaphragm to the iliac crests. The arterial phase of the same region started at approximately 20–30 s after the administration of contrast agent, followed by the portal phase (30–40 s). Reconstructions were performed on a GE Advantage Windows 3D workstation (GE Healthcare, Waukesha, WI, USA) with the reconstitution thickness set at 1–2 mm. The detailed scanning parameters were listed as follows: tube voltage, 120 or 100 kVp; tube current, 150–600 mA; slice thickness, 1.25 mm; and pitch, 1.375. All patients received an intravenous, nonionic contrast agent (iodine concentration, 370 mg/mL; volume, 1.5–2.0 mL/kg of body weight; contrast type, iopromide injection (Bayer Pharma AG, Leverkusen, Germany)) at a rate of 3–5 mL/s. Then, 20-mL saline was injected after contrast injection.

The investigated individuals underwent contrast-enhanced CT imaging with one of the following systems: Sensation 64 CT (Siemens), Sensation 16 CT (Siemens), or 64 LightSpeed VCT (GE Healthcare). Triple-phase CT examinations were conducted, i.e., non-enhanced, arterial, and portal vein phases. Abdominal scouts were acquired from the dome of the diaphragm to the iliac crests. The arterial phase of the same region was started at approximately 20–30 s after contrast agent administration and was followed by the portal phase (30–40 s). The reconstructions were conducted on a GE Advantage Windows 3D workstation (GE Healthcare, Waukesha, WI, United States), and the reconstitution thickness was set at 1–2 mm. The detailed scanning parameters are listed as follows: tube voltage, 120 or 100 kVp; tube current, 150–600 mA; slice thickness, 1.25 mm; and pitch, 1.375. All patients received an intravenous, non-ionic contrast agent (iodine concentration, 370 mg/ml; volume, 1.5–2.0 ml/kg of body weight; contrast type, Omnipaque 300, GE Healthcare, Ireland) at a rate of 3–5 ml/s. A volume of 20 ml saline was injected after the injection of the contrast.